Uemura M, Tsujii T, Fukui H, Kita K, Takaya A, Tsukamoto N, Nakayama M, Matsumoto M, Tamura M
Scand J Gastroenterol. 1986 Jan;21(1):75-81. doi: 10.3109/00365528609034626.
Changes in urinary PGE2 and PGF2 alpha excretion in chronic liver diseases were observed in relation to renal hemodynamics and sodium balance. After equilibration on a 110-170-meq sodium diet, daily urine collections were analyzed for PGE2 and PGF2 alpha by a new extraction and radioimmunoassay method. PGE2 was significantly greater in cirrhotics than in healthy subjects and in chronic hepatitis. The value was greater in cirrhotics with ascites than in those without ascites (p less than 0.05). PGF2 alpha did not differ among the groups. In cirrhotics PGE2 was correlated negatively with creatinine clearance (Ccr)(r = -0.76, p less than 0.001). After administration of 200 mg indomethacin, a significant fall in Ccr was seen only in cirrhotics with ascites. The percentage fall in PGE2 after indomethacin correlated with that in Ccr (r = 0.89, p less than 0.05) and with that in urinary sodium excretion (r = 0.68, p less than 0.02). These results suggest that PGE2 is essential in the maintenance of renal function in liver cirrhosis with ascites.
观察慢性肝病患者尿中前列腺素E2（PGE2）和前列腺素F2α（PGF2α）排泄量的变化，并分析其与肾血流动力学及钠平衡的关系。在110 - 170毫当量钠饮食条件下达到平衡后，采用新的提取和放射免疫测定法对每日收集的尿液进行PGE2和PGF2α分析。肝硬化患者尿中PGE2水平显著高于健康受试者和慢性肝炎患者。有腹水的肝硬化患者尿中PGE2水平高于无腹水者（p < 0.05）。各组间PGF2α水平无差异。在肝硬化患者中，PGE2与肌酐清除率（Ccr）呈负相关（r = -0.76，p < 0.001）。给予200毫克吲哚美辛后，仅在有腹水的肝硬化患者中观察到Ccr显著下降。吲哚美辛给药后PGE2下降百分比与Ccr下降百分比相关（r = 0.89，p < 0.05），也与尿钠排泄下降百分比相关（r = 0.68，p < 0.02）。这些结果表明，PGE2对伴有腹水的肝硬化患者肾功能的维持至关重要。
